Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies
Constantine S Tam, John F Seymour, Michael Brown, Philip Campbell, John Scarlett, Craig Underhill, David Ritchie, Rodney Bond, Andrew P Grigg
Haematologica | FERRATA STORTI FOUNDATION | Published : 2005
Whether the addition of rituximab to fludarabine and cyclosphosphamide (FC) increases early or late infection risk remains poorly defined. This retrospective analysis of 160 patients treated with FC+/-rituximab found no evidence of increased infection among patients receiving FC+rituximab, providing some evidence of safety for the continued exploration of this regimen.
this study was supported in part by research funding from Schering AG inc.